Development and Validation of a MicroRNA Signature Predictive of Local-Regional Recurrence and Overall Survival after Resection of Pancreatic Ductal Adenocarcinoma (PDAC)

Prognosis for PDAC remains poor despite oncologic resection and adjuvant chemotherapy, with local-regional recurrence (LRR) rates as high as 60-70% at 2 years and 5-year overall survival (OS) of less than 30%. The use of postoperative radiotherapy (RT) is controversial, and identification of novel molecular markers may assist in selecting patients at high risk for LRR who might benefit from RT. We hypothesized we could identify a novel microRNA...